Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 8, 2026JAMA

Tenecteplase for Acute Non–Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGaoting MaRMRan MoYZYingting Zuo

Discussion

Loading...

Member takes

Overview

Clinical trial assesses efficacy of tenecteplase for stroke recovery in adults, suggesting improved outcomes but increased risks.

Key Points

  • To evaluate the efficacy and safety of tenecteplase for non–large vessel occlusion ischemic stroke administered 4.5 to 24 hours after onset.
  • Randomized open-label blinded endpoint clinical trial
  • Conducted across 48 centers in China
  • Involved 566 patients with non–large vessel occlusion stroke
  • Participants received either tenecteplase or standard medical treatment
  • 43.6% of patients in the tenecteplase group achieved an excellent functional outcome compared to 34.2% in the control group
  • Higher incidence of symptomatic intracranial hemorrhage at 2.8% with tenecteplase versus 0% in control
  • Mortality at 90 days was 5.0% for the tenecteplase group and 3.2% for the control group

Cite This Study

Ma et al. (2026) studied this question.

synapsesocial.com/papers/698828ab0fc35cd7a88485dahttps://doi.org/10.1001/jama.2026.0210
View Full Paper
Ask AI
Bookmark
Share